Passiflora incarnata L. — A climbing vine native to the southeastern United States and Mexico, whose flavonoids — chrysine, vitexin, and 6-methoxyflavanone — act on GABA-A receptors and central benzodiazepine binding sites to produce anxiolysis equivalent to oxazepam in an RCT, while a unique benzoflavone moiety attenuates withdrawal from morphine, cannabis, nicotine, and benzodiazepines in documented studies.
Passiflora incarnata is a climbing woody vine native to the southeastern United States and Mexico, cultivated also in the south of France, Brittany, and Anjou for the European herbal market. Its name "passion flower" was given by Jesuit missionaries who saw in each part of the plant a symbol of the Passion of Christ — the three-pointed flowers as the lance, the tendrils as the whip, the three styles as the nails, the stigmas as the sponge. Pharmacologically, the dried aerial parts contain a complex of flavonoids that act synergistically on GABAergic and benzodiazepine receptor systems — producing anxiolytic and sedative effects that isolated individual compounds cannot replicate.
Passionflower was known to the Aztecs long before European contact. When Spanish Jesuit missionaries encountered Passiflora incarnata in the Americas, they named it "passion flower" — reading Christian symbolism into each botanical structure: the three-pointed flowers recalled the lance that pierced Christ's side; the coiling tendrils, the whip of the flagellation; the three styles, the nails of the cross; the stigmas, the sponge soaked in vinegar. The white and purple-blue colours symbolised purity and heaven.
This deeply symbolic naming made passionflower one of the most culturally embedded medicinal plants of the colonial Americas. It entered European pharmacopoeias during the 18th century and became established in French herbal medicine as a sedative and anxiolytic — a use that modern clinical pharmacology has validated through multiple randomised controlled trials. It is now cultivated commercially in Southern France, Brittany, and Anjou to meet European demand.
A critical quality issue: the aerial parts of P. incarnata are at risk of adulteration with two inferior species. Passiflora edulis — the commercial passion fruit plant — has leafy stems that are nearly pharmacologically inactive and can be substituted in bulk preparations.[1] Passiflora coerulea — an ornamental garden species with five-lobed (not three-lobed) leaves — has also been detected as an adulterant. Always verify that purchased material specifies Passiflora incarnata by Latin name, not "passionflower" generically.
⚠ Adulteration Risk — Always Verify the Latin Name
Passiflora edulis (passion fruit) aerial parts are nearly inactive and documented as an adulterant in P. incarnata preparations.[1] P. coerulea (ornamental blue passionflower) can also substitute. Verify your supplement specifies Passiflora incarnata L. by Latin name with a certificate of analysis confirming flavonoid content. Generic "passionflower" labelling without a Latin name is a red flag.
Four distinct flavonoid structures each with a unique CNS mechanism — and a critical myth about beta-carbolines that most competitor content gets completely wrong.
⚠ Myth Correction — Beta-Carbolines Do NOT Cause Passionflower's Sedative Effects
Harmine is not responsible for passionflower's anxiolytic effects
A persistent and dangerous myth states that passionflower contains harmine — an alkaloid of Ayahuasca (Banisteriopsis caapi) that is a MAO inhibitor and at high doses a hallucinogen. This is partially true but pharmacologically irrelevant: beta-carboline alkaloids (harmane, harmine, harmol) are present in P. incarnata only at trace levels, if at all — the primary phytochemistry reference (Bruneton, Pharmacognosie, 4th ed.) describes them as "extrêmement mineurs" (extremely minor constituents).[3] With one exception, only harmane has been detected, and only by some researchers.[2]
More critically: beta-carbolines are CNS stimulants — not sedatives. They cannot account for passionflower's anxiolytic and sleep-inducing effects. The sedative and anxiolytic activity is entirely attributable to the flavonoid fraction — chrysine, vitexin, isovitexin, orientine, and 6-methoxyflavanone — acting on GABA-A receptors and central benzodiazepine binding sites. Any content attributing passionflower's calming effects to harmine or beta-carbolines is pharmacologically incorrect.
Chrysine (5,7-dihydroxyflavone) is a competitive ligand for central benzodiazepine receptors — it binds the same allosteric site on the GABA-A receptor complex as diazepam (Valium).[17][18] This direct benzodiazepine receptor binding produces anxiolytic effects in animal models. Critically, chrysine is a partial agonist rather than a full agonist at this receptor site — it produces anxiolytic effects without the full dependency-inducing, memory-impairing, and respiratory-depressing effects of pharmaceutical benzodiazepines. This partial agonism is the pharmacological basis for passionflower's clinical use in benzodiazepine withdrawal — it provides receptor-level support without perpetuating full agonist dependence.
6-Methoxyflavanone is characterised as a novel anxiolytic agent with a distinct behavioural and pharmacokinetic profile.[19] Beyond anxiolytic activity, it has documented efficacy in attenuating mechanical allodynia (abnormal pain from non-painful stimuli) and vulvodynia in a diabetic neuropathic pain model.[42] This makes 6-methoxyflavanone the only passionflower flavonoid with both anxiolytic and analgesic/anti-allodynic activity — explaining why passionflower has clinical evidence for neuropathic pain and vulvodynia, which most practitioners and consumer sites have no awareness of.
Vitexin, isovitexin, orientine, and isoorientine are the principal flavone glycosides of P. incarnata aerial parts. They are the proposed primary anxiolytic actives based on GABAergic system modulation — Grundmann et al. (2008) demonstrated that a phytochemically characterised passionflower extract produces anxiolytic activity via the GABAergic system.[12] Appel et al. (2011) specifically confirmed GABA system modulation by P. incarnata.[13] Vitexin alone has documented anticonvulsant and anxiolytic-like effects in murine models.[15]
A tri-substituted benzoflavone moiety isolated from P. incarnata has a unique pharmacological profile distinct from the anxiolytic flavonoids: it counteracts withdrawal effects of morphine, cannabinoids (delta-9-THC), nicotine, and alcohol in animal models.[20][21] It also attenuates benzodiazepine dependence in mice.[32] This benzoflavone acts as a receptor modulator that reduces neurological craving and withdrawal discomfort — a mechanism that positions passionflower uniquely as a broad-spectrum anti-addiction botanical with no equivalent in other anxiolytic plants.
⚠ Standardisation — Why Extract Quality Determines Clinical Effect
The total extract is active; isolated individual compounds are not — standardisation is essential.
A foundational finding in passionflower research (Soulimani et al., 1997): the total extract produces anxiolytic and sedative activity, but isolated individual compounds — alkaloids, flavonoids, and maltol tested separately — do not produce the same effects.[9] The activity is synergistic, not attributable to any single compound. This makes standardisation of the total flavonoid fraction critical — and makes generic "passionflower" products without verified flavonoid profiles unreliable. A separate study (Dhawan et al., 2002) confirmed that different preparations of P. incarnata produce significantly different anxiety profiles — the form of preparation matters as much as the dose.[26]
Dried aerial parts only. Preparation method determines whether the effect is primarily sedative (aqueous) or anxiolytic (hydroalcoholic) — a clinically important distinction.
Dried aerial parts of P. incarnata, which may include flowers and/or fruits. Must be specifically Passiflora incarnata L. — not P. edulis (passion fruit, nearly inactive) or P. coerulea (ornamental, five-lobed leaves). Contains the full spectrum of anxiolytic flavonoids, benzoflavone, maltol, and minimal alkaloids.
Chrysine · Vitexin · Orientine · 6-Methoxyflavanone
The source makes an explicit distinction documented in the literature: sedative effect = aqueous extract (tea/infusion); anxiolytic effect = hydroalcoholic extract (tincture/dry extract).
This distinction matters clinically: for sleep onset, aqueous infusion may be preferable. For daytime anxiety management without sedation, standardised dry extract or tincture is more appropriate. Most consumers and many practitioners are unaware of this preparation-specific pharmacology.
From the primary clinical literature. Preparation form determines pharmacological effect — see Parts Used section above.
The aerial parts contain a complex of flavonoids — the primary active fraction — plus minor alkaloids (pharmacologically negligible), pyrones, cyanogenic glucosides, and trace essential oil. Bud and essential oil fractions are absent from the source.
Core clinical property — sedative and anxiolytic activity confirmed in multiple animal models and human RCTs.[5][7][8] Activity produced by synergy of entire flavonoid complex — not any individual compound.[9][10] Critically: sedative effect via aqueous extract; anxiolytic effect via hydroalcoholic extract — preparation determines the primary effect.
Passionflower induces sleep and improves subjective sleep quality. A double-blind RCT (Ngan & Conduit, 2011) confirmed significantly better sleep quality with passionflower tea vs placebo.[23] A 2024 RCT (Harit et al., Cureus) confirms improvement in both stress and sleep quality.[5] Animal data shows hippocampal neurogenesis improvement in sleep-disordered mice, with proposed Alzheimer's preventive implication.[24]
The tri-substituted benzoflavone moiety counteracts withdrawal effects of morphine,[33] cannabinoids (delta-9-THC),[35] nicotine,[20] and alcohol[21] in animal models. Human evidence: passionflower for opioid withdrawal (Akhondzadeh et al., 2001)[33] and benzodiazepine withdrawal 78.4% success (Dubois et al., 2019).[29] Few other anxiolytic plants have evidence across this range of addictions.
Antispasmodic and CNS depressant activity via maltol — present in small quantity but documented to induce smooth muscle relaxation.[4] The flavonoid complex additionally contributes to antispasmodic effects via GABAergic smooth muscle modulation. Clinically relevant for psychogenic abdominal pain (colites), psychosomatic spasms, and nervous agitation with somatic manifestations.
Passionflower improves memory and neurogenesis in sleep-disordered mice — specifically by promoting hippocampal neurogenesis in a DBA/2 mouse model of sleep-induced cognitive deficits.[24] This hippocampal neurogenesis mechanism has proposed relevance to Alzheimer's disease prevention — though this remains a preclinical finding. The combination of sleep improvement + hippocampal neurogenesis positions passionflower as a cognitively relevant sleep aid.
Passionflower attenuates neuropathic allodynia and vulvodynia via GABAergic and opioid antinociceptive mechanisms (Aman et al., 2016).[41] Specifically, 6-methoxyflavanone attenuates mechanical allodynia and vulvodynia in diabetic neuropathic pain (Akbar et al., 2016).[42] These indications are essentially absent from all competitor content — a significant differentiation opportunity.
Passionflower is specifically indicated for cardiac erethism in adults — the neurogenic palpitations and cardiac hypersensitivity that occur in anxious patients without organic cardiac disease. This is a traditional phytotherapy indication ("états neurotoniques") that maps to the modern concept of anxiety-driven somatic cardiac symptoms. The GABAergic anxiolytic mechanism directly reduces the sympathetic nervous overactivation that produces these palpitations.
Methanol extract of P. incarnata leaves demonstrated aphrodisiac activity in male mice (Dhawan et al., 2003).[25] The mechanism is not fully characterised but may relate to anxiolytic reduction of performance anxiety or direct pro-sexual receptor effects. This is a preclinical finding only — no human clinical evidence exists for this application.
A derivative of alpha-naphthoflavone (7,8-benzoflavone) present in P. incarnata is an aromatase inhibitor — inhibiting the enzyme that converts androgens to oestrogens. This pharmacological property has potential clinical relevance in oestrogen-sensitive conditions, though no clinical trials specifically investigating this application in passionflower are cited in the primary source. This is a mechanistic finding; clinical implication remains to be established.
The primary source describes passionflower as "the plant of nervous excitement and neuro-sensory hypersensitivity" — for those hypersensitive to noise, smells, and multiple stressors. It calms, relaxes, and is active in withdrawal syndromes.
Passionflower operates through at least three parallel CNS receptor systems — GABA-A, benzodiazepine receptor, and opioid — plus the unique anti-addiction benzoflavone pathway.
The primary anxiolytic mechanism of passionflower operates through the GABAergic system — the main inhibitory neurotransmitter system of the brain. Multiple studies confirm this mechanism: Grundmann et al. (2008) demonstrated that a phytochemically characterised extract produces anxiolytic effects via the GABAergic system,[12] and Appel et al. (2011) confirmed modulation of the gamma-aminobutyric acid (GABA) system by P. incarnata.[13] Elsas et al. (2010) showed that passionflower extracts elicit GABA currents in hippocampal neurons in vitro and show anxiogenic and anticonvulsant effects in vivo, with results varying by extraction method.[14] The flavones vitexin, isovitexin, orientine, and isoorientine are proposed as the primary GABAergic actives.
Chrysine (5,7-dihydroxyflavone) and apigenine are competitive ligands for central benzodiazepine receptors[17][18] — the allosteric sites on the GABA-A receptor complex where diazepam binds. By occupying these sites as partial agonists, they produce anxiolytic effects by facilitating GABAergic chloride channel opening, without the full agonist effects that produce dependence, memory impairment, and respiratory depression with pharmaceutical benzodiazepines. This partial agonism is the direct pharmacological basis for passionflower's clinical utility in benzodiazepine withdrawal — it provides receptor support without perpetuating full dependence.
Nassiri-Asl et al. (2007) demonstrated that anticonvulsant effects of P. incarnata aerial parts involve both benzodiazepine and opioid receptors.[16] Opioid receptor contribution also explains the allodynia-attenuating effects documented by Aman et al. (2016) — neuropathic pain relief via "GABAergic and opioidergic antinociceptive and behavioural mechanisms."[41] This dual GABAergic + opioidergic mechanism is unusual for a plant extract and positions passionflower uniquely between pure anxiolytics (GABA-only) and broader neuromodulators, explaining its effectiveness in both anxiety and pain applications.
The tri-substituted benzoflavone moiety operates through a mechanism distinct from the anxiolytic flavonoids. Dhawan et al. demonstrated its ability to reverse nicotine-induced locomotor hyperactivity and dependence,[20] suppress alcohol cessation-oriented hyperanxiety,[21] and attenuate benzodiazepine dependence[32] — all through what appears to be a modulation of substance-specific receptor or reward pathway sensitisation, rather than simple GABA-A agonism. The breadth of anti-addiction activity across structurally unrelated substances (opioids, cannabinoids, nicotine, alcohol, benzodiazepines) suggests the benzoflavone acts on a common downstream reward pathway rather than substance-specific receptors.
Two of the most evidence-based herbal anxiolytics and sleep aids — with complementary GABAergic mechanisms and distinct strongest applications. See our full Valeriana officinalis page for the complete valerian pharmacology.
Clinical Bottom Line
Choose passionflower when anxiety is the primary complaint, when addiction withdrawal support is needed, when neuropathic pain accompanies anxiety, or when preoperative anxiolysis without sedation is the goal. Choose valerian when sleep maintenance is the primary issue or when pure insomnia without significant daytime anxiety dominates. Both can safely be combined — their GABAergic mechanisms operate at different points in the pathway (passionflower: GABA-A receptor and benzodiazepine site; valerian: GABA reuptake inhibition), producing additive anxiolytic and sedative effects without pharmacokinetic interaction. See our Valeriana officinalis monograph for the complete valerian comparison.
Generally well tolerated at standard doses. Two pharmacokinetic interactions (benzodiazepines and OATP transporters) require specific attention.